Mehmet Mutlu Kıdı

seyhan state hospital

H指数:3

被引数:32

浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre-Treatment CD44 and CD47 Expression and Pathological Complete Response After Neoadjuvant Therapy in Breast Cancer: An Exploratory Single-Center Study

术前CD44和CD47表达与乳腺癌新辅助治疗后的病理完全缓解：一项探索性单中心研究

International Journal of Molecular Sciences

IF4.9

2026-10-290

Prognostic Value of Pretreatment Modified Glasgow Prognostic Score in Nivolumab-Treated Advanced Non-Small Cell Lung Cancer

Nivolumab治疗晚期非小细胞肺癌中治疗前改良格拉斯哥预后评分的预后价值

Journal of Clinical Medicine

IF2.9

2026-10-010

Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?

是否存在一个肿瘤比例评分阈值，在该阈值下，肿瘤细胞PD-L1能够为大型B细胞淋巴瘤的国际预后指数提供额外的预后信息？

Diagnostics

IF3.3

2026-09-190

Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

索拉非尼治疗放射性碘难治性分化型甲状腺癌患者的真实世界结果及预后因素：一项多中心研究

Journal of Clinical Medicine

IF2.9

2026-06-240

OAAI

Suheda Atas Ipek; Sendag Yaslikaya; Ismail Oguz Kara; Tolga Koseci; Ertugrul Bayram; Esra Asarkaya; Hatice Asoglu; Mehmet Turker; Abdurrahman Aykut; Seda Jeral Evinc; Ozkan Alan; Mehmet Emin Yilmaz; Ozturk Ates; Hatime Arzu Yasar; Mehmet Kayaalp; Esra Asik; Atila Yildirim; Burcu Bacak; Meltem Baykara; Dicle Yurdatap Koc; Muhammed Bekir Hacioglu; Suleyman Alkan; Ferhat Ekinci; Ahmet Burak Agaoglu; Mesut Yilmaz; Ilhan Hacibekiroglu; Mustafa Karaca; Taliha Guclu Kantar; Gamze Gokoz Dogu; Tuba Karacelik; Melek Karakurt Eryilmaz; Teoman Sakalar; Sedat Biter; Mehmet Mutlu Kıdı; Yasemin Aydınalp Camadan; Mahmut Buyuksimsek

Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey

帕唑帕尼在老年晚期软组织肉瘤患者中的疗效和耐受性：来自土耳其的多中心真实世界研究

Journal of Clinical Medicine

IF2.9

2026-06-230

Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study

大型语言模型（ChatGPT-5）作为妇科肿瘤学肿瘤委员会临床决策支持工具的可行性与一致性：一项盲法、多观察者研究

Journal of Clinical Medicine

IF2.9

2026-06-090

Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors

解剖学定位对侵袭性纤维瘤病系统性炎症标志物和免疫检查点CD47的影响

Journal of Clinical Medicine

IF2.9

2026-05-240

Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

比较固定剂量与体重基础剂量纳武利尤单抗治疗非小细胞肺癌患者的疗效

Scientific Reports

IF3.9

2026-05-080

OAAI

Muhammet Cengiz; Oktay Bozkurt; Ayse Nuransoy Cengiz; Deniz Can Guven; Elif Sahin; Emel Mutlu Ozkan; Mustafa Ersoy; Ezgi Turkoğlu; Sedat Yildirim; Erdem Kolemen; Beyza Unlu; Hayati Arvas; Mehmet Mutlu Kidi; Sedat Biter; Latif Karahan; Mustafa Erman; Ismail Oguz Kara; Meltem Baykara; Pervin Can Sanci; Anıl Karakayali; Umut Kefeli; Devrim Cabuk; Saadettin Kilickap; Teoman Sakalar; Nargiz Majidova; Berrak Mermit Ercek; Muslih Urun; Gözde Agdas; Duygu Bayir; Cengiz Akosman; Erkam Kocaaslan; Havva Yesil Cinkir; Aslihan Ezgi Apaydin Rollas; Mevlude Inanc; Metin Ozkan

Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

基线维生素D状态及接受纳武利尤单抗治疗的晚期非小细胞肺癌患者的临床结局

Scientific Reports

IF3.9

2026-04-140

OAAI

Gözde Ağdaş; Duygu Bayir; Elif Şahin; Muhammet Cengiz; Deniz Can Güven; Mehmet Salim Demir; Ertuğrul Bayram; Duygu Özaşkın; Meltem Baykara; Oktay Bozkurt; Mevlüde İnanç; Metin Özkan; Ayşe Nuransoy Cengiz; Mustafa Erman; Umut Kefeli; Emel Mutlu Özkan; Erkam Kocaaslan; Devrim Çabuk; Saadettin Kiliçkap; Pervin Can Sanci; Muslih Urun; Teoman Sakalar; Cengiz Akosman; Erdem Kolemen; Ezgi Turkoğlu; Anıl Karakayali; Mustafa Ersoy; Sedat Yildirim; Latif Karahan; Hayati Arvas; Mehmet Mutlu Kidi; Sedat Biter; Berrak Mermit Ercek; Nargiz Majidova; Havva Yesil Cinkir; Aslihan Ezgi Apaydin Rollas; İbrahim Karadağ

Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

免疫检查点抑制剂在错配修复缺陷型结直肠癌患者中的疗效、安全性和生存结局：一项回顾性、多中心研究

Journal of Clinical Medicine

IF2.9

2026-02-270

OAAI

The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

接受免疫疗法治疗的晚期肺癌患者中，早期肺部免疫预后指数变化的预后意义

Discover Oncology

IF2.9

2026-02-210

OAAI

Muhammet Cengiz; Oktay Bozkurt; Ayşe Nuransoy Cengiz; Mevlude Inanc; Metin Ozkan; Emel Mutlu Ozkan; Deniz Can Guven; Mustafa Erman; Latif Karahan; Elif Sahin; Anıl Karakayali; Pervin Can Sanci; Umut Kefeli; Devrim Cabuk; Erdem Kolemen; Mehmet Mutlu Kidi; Sedat Biter; Tolga Koseci; Muslih Urun; Berrak Mermit Ercek; Duygu Bayir; Gözde Agdas; Teoman Sakalar; Nargiz Majidova; Sedat Yildiz; Hacer Demir; Cengiz Akosman; Mustafa Ersoy; Saadettin Kilickap; Erkam Kocaaslan; Ezgi Turkoğlu; Sedat Yildirim; Hayati Arvas; Havva Yesil Cinkir; Aslihan Ezgi Apaydin Rollas

Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

血管紧张素系统抑制剂对转移性非小细胞肺癌中尼鲁单抗治疗临床结局的影响

Expert Review of Anticancer Therapy

IF2.8

2026-01-010

PRE

Ozkan, Emel Mutlu; Karadag, Ibrahim; Sahin, Elif; Cengiz, Ayse Nuransoy; Cengiz, Muhammet; Guven, Deniz Can; Bozkurt, Oktay; Inanc, Mevlude; Ozkan, Metin; Kefeli, Umut; Cabuk, Devrim; Erman, Mustafa; Kilickap, Saadettin; Koseci, Tolga; Bayir, Duygu; Demir, Hacer; Yildiz, Sedat; Urun, Muslih; Sakalar, Teoman; Majidova, Nargiz; Akosman, Cengiz; Ersoy, Mustafa; Sanci, Pervin Can; Kolemen, Erdem; Agdas, Gozde; Kocaaslan, Erkam; Turkoglu, Ezgi; Yildirim, Sedat; Ercek, Berrak Mermit; Karakayali, Anil; Arvas, Hayati; Kidi, Mehmet Mutlu; Biter, Sedat; Cinkir, Havva Yesil; Karahan, Latif; Rollas, Aslihan Ezgi Apaydin

Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring

JOURNAL OF CLINICAL MEDICINE

IF2.9

2025-03-010

OAAI

Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

SCIENTIFIC REPORTS

IF3.9

2024-11-300

OAAI

Can the Pathological Response in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Treatment Be Predicted by the CEA/Albumin and CRP/Albumin Ratios?

JOURNAL OF CLINICAL MEDICINE